Rulizumab batoclimab NMOSD gMG

Indicated For

NMOSD, gMG

About This Medication

# Batoclimab Patient Guide: How to Get Batoclimab at Low or No Cost **Important Notice: Batoclimab is currently an investigational drug and not FDA-approved.** As of March 2026, no commercial patient assistance program exists because batoclimab remains in clinical trials for conditions like generalized myasthenia gravis (gMG). This guide provides general information on pharmaceutical assistance programs and steps to explore access options through trials or expanded access. Always consult your doctor for personalized advice.[1][2][6] ## About Batoclimab Batoclimab (also known as IMVT-1401 or HBM9161) is an experimental **monoclonal antibody** that targets the neonatal Fc receptor (FcRn). By blocking FcRn, it reduces harmful autoantibodies in the body, which may help treat autoimmune diseases like **generalized myasthenia gravis (gMG)**, where muscles weaken due to communication issues between nerves and muscles.[4][6][8] In clinical trials, batoclimab is given as a **subcutaneous injection** (under the skin) once weekly at doses of 340 mg or 680 mg. Phase 3 studies, like the FLEX trial (NCT05403541), test it as induction (12 weeks) and maintenance therapy (12 weeks), with long-term extensions up to 64 weeks or more. Patients showing improvement (e.g., ≥2-point change in MG-ADL score) may continue treatment.[1][2][6][9] **Key Trial Findings:** In a phase 3 trial of 131 antibody-positive gMG patients, batoclimab improved daily activities (MG-ADL score) in 58.2% of patients vs. 31.3% on placebo.[4] It's also studied for CIDP and other conditions by Immunovant and partners like Harbour BioMed.[3][5] Since batoclimab isn't approved, access is limited to clinical trials or potential expanded access programs. No standard prescription assistance applies yet. ## Who Qualifies for Assistance? Traditional patient assistance programs (PAPs) from drug makers help uninsured or low-income patients get free or low-cost meds. However, with batoclimab's investigational status, **no dedicated PAP exists**. Manufacturer **Immunovant** (U.S./Canada development) has no listed program on resources like RxAssist.[7] **General Eligibility for Future PAPs (Hypothetical Based on Standard Programs):** If approved, expect criteria like: - U.S. resident - No or limited prescription insurance - Household income at or below **400-500% of the Federal Poverty Level (FPL)** ## Income Eligibility Breakdown Since no specific program exists, here's a **sample table** based on typical U.S. PAPs (e.g., 400% FPL for 2026 estimates). Check annually as FPL updates. | Household Size | Max Annual Income (400% FPL) | Notes | |----------------|------------------------------|-------| | 1 (Individual) | ~$60,000 | Approximate; varies by program | | 2 (Couple) | ~$81,000 | Includes dependents | | 3 | ~$102,000 | Some allow up to 500% FPL | | 4 | ~$122,000 | Excludes certain deductions | **Notes:** Programs often exclude Medicare Part D or certain insurances. Verify with manufacturer post-approval.[7] ## Insurance Requirements Most PAPs require **no prescription drug coverage** or proof of denial from insurance. **Medicare patients** are often ineligible unless they qualify for Extra Help (low-income subsidy). If batoclimab is approved, commercial insurance may cover it, but high copays could still qualify you for co-pay assistance.[7] ## Step-by-Step Application Process **Current Options (No PAP Available):** 1. **Ask Your Doctor About Clinical Trials:** Search ClinicalTrials.gov for batoclimab (e.g., NCT05403541). Eligibility often includes gMG with MG-ADL ≥5, antibody-positive.[1][2][6] 2. **Expanded Access:** Contact Immunovant for compassionate use if trials aren't an option. 3. **Monitor Approval:** Track FDA updates; if approved, visit Immunovant's site for PAP details. 4. **General Resources:** Use RxAssist.org or NeedyMeds.org to search for updates.[7] 5. **Physician Prescription:** Required for any access. 6. **Submit Application:** Hypothetically, download form, provide income docs, mail/fax. **Required Documents (Standard for PAPs):** Proof of income (tax returns, paystubs), ID, prescription, insurance denial letter. ## Timeline and Delivery **Trials:** Enrollment varies; treatment starts post-screening (weeks). Induction: 12 weeks weekly injections; maintenance: 12 weeks. Long-term: up to 52+ weeks.[1][9] Delivery via clinic. **Hypothetical PAP:** Processing 2-4 weeks; meds shipped to doctor's office or home every 1-3 months. ## Alternatives if Denied or Ineligible - **Other gMG Treatments:** Efgartigimod (Vyvgart), rituximab, IVIG, or steroids with PAPs. - **Biosimilars:** None listed for batoclimab.[ ] - **Trial Re-entry:** If flare in extensions.[1] - **State Programs:** Check Medicaid or 340B clinics. ## Disclaimer This guide is for informational purposes only and not medical advice. Batoclimab is **not FDA-approved**; access is trial-based. Consult your healthcare provider. Program details may change; verify with Immunovant or official sources. Word count: ~950.

Program information last verified: March 30, 2026